Trellis Bioscience Inc

Trellis Bioscience, located in South San Francisco, CA, is a biotechnology company specializing in the development of native human monoclonal antibodies for the treatment of infectious diseases and cancer. Their innovative CellSpot platform allows for the discovery of highly effective antibodies, including their lead product TRL1068, which has shown promising results in reducing biofilm burden in Prosthetic Joint Infections. With a strong pipeline of products targeting viruses such as HCMV, RSV, and influenza, Trellis Bioscience is at the forefront of the rapidly growing mAb segment of the pharmaceutical industry.

By leveraging their expertise in monoclonal antibody discovery, Trellis Bioscience aims to revolutionize the treatment of challenging diseases, including biofilm-embedded bacterial infections and cancer. Their ongoing clinical trials, supported by partnerships like CARB-X, demonstrate their commitment to advancing medical innovation and improving patient outcomes. With a focus on safety, efficacy, and cost-effectiveness, Trellis Bioscience is poised to make a significant impact in the field of biotechnology.

Generated from the website